Yavor Y.
- Country
- Germany
- Department
- 1120: Klinik für Neurologie
Research Overview
- Efficacy of efgartigimod alfa as add‑on to intravenous methylprednisolone for moderate‑to‑severe attacks in patients with multiple sclerosis, NMOSD or MOGAD
- Efficacy and Tolerability of Ofatumumab Versus First-Line Disease-Modifying Therapies in Newly Diagnosed Relapsing Multiple Sclerosis Patients
- Phase III Randomized, Double-Blind, Placebo-Controlled Study of Iptacopan in Patients with Generalized Myasthenia Gravis
Data & Insights
Has run more than one trial at 51 of 160 partner sites.
Specializations
Neurological Disorders
This investigator specializes in studying multiple sclerosis (MS), with particular emphasis on evaluating innovative therapeutic approaches for both newly diagnosed and previously treated patients.
- Relapsing Multiple Sclerosis (RMS)
- Treatment-naïve MS Patient Care
- Long-term Disease Management
Their research encompasses the assessment of various disease-modifying treatments and their comparative effectiveness in neurological conditions.
Therapeutic Development
The investigator focuses on evaluating B-cell targeting therapies and their application in autoimmune conditions, specifically examining long-term safety and efficacy profiles.
- Novel Treatment Approaches
- Self-administered Therapeutics
- Treatment Optimization
Their work includes assessment of first-line treatment options and comparison of different therapeutic modalities.
Clinical Assessment
The investigator's expertise extends to long-term safety evaluation and monitoring of therapeutic interventions in chronic neurological conditions.
- Safety Profile Analysis
- Treatment Efficacy Assessment
- Patient Response Monitoring
Their research involves comprehensive evaluation of treatment tolerability and therapeutic outcomes in MS patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.